Antibodies News and Research

RSS

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.

From Baxter International Inc. 16 Apr 2015

NIST researchers develop new 2D NMR fingerprinting method to measure monoclonal antibodies

National Institute of Standards and Technology researchers at the Institute for Bioscience and Biotechnology Research have demonstrated the most precise method yet to measure the structural configuration of monoclonal antibodies (mAbs), an important factor in determining the safety and efficacy of these biomolecules as medicines.

16 Apr 2015

Sterillo: The world's most hygienic hand dryer destroys bacteria and viruses

Research by Sterillo, the world's most hygienic hand dryer, has revealed a nation attempting to dodge germs and smelly washrooms. Whilst they are in fact, ignorantly smothering themselves in germs and bacteria every time they visit a public or restaurant toilet.

15 Apr 2015

Researchers discover new biomarker to identify women with uterine cancer

Researchers at Uppsala University have, together with researchers from Turku and Bergen, discovered a new biomarker which makes it possible to identify women with uterine cancer who have a high risk of recurrence.

15 Apr 2015

Humabs BioMed reports clinical milestone in medImmune partnership

Humabs BioMed SA, a leading Swiss antibody therapeutics company, today announced that a novel antibody developed through its proprietary Cellclone technology will be investigated for the treatment of influenza A...

14 Apr 2015

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

MorphoSys's collaboration with Janssen has resulted in three clinical programs to date, two of which are in phase 2 development and one, guselkumab, in phase 3 in psoriasis (most advanced trial)...

14 Apr 2015

Inova Diagnostics gains FDA de novo clearance for NOVA View automated digital IFA microscope

Inova Diagnostics, the worldwide leader in autoimmune diagnostic reagents and systems for the clinical laboratory, announced today that the United States Food and Drug Administration has cleared NOVA View, an automated digital IFA (indirect fluorescent assay) microscope, through the de novo classification process.

12 Apr 2015

VolitionRx adds three new laboratory automation systems to expedite sample analysis for its large ongoing clinical trials

Using its first installed robot, VolitionRx has recently completed the analysis of a first NuQ® assay on the complete set of 4,800 blood samples for its large retrospective, symptomatic population colorectal cancer study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark.

10 Apr 2015

New automated tool rapidly delivers large particles into mammalian cells

A new device developed by UCLA engineers and doctors eventually help scientists study the development of disease, enable them to capture improved images of the inside of cells and lead to other improvements in medical and biological research.

10 Apr 2015

Protein-degrading enzyme can trigger strong allergic reactions through skin

Papain is an important industrial protein-degrading enzyme that is used, for example, in the food and cosmetic industries.

10 Apr 2015

Enhanced biodiversity of worms, germs associated with better immune function, overall health

A growing body of evidence in the medical community holds that greater diversity of bacteria and even worms in the digestive tract offers protection against a variety of allergic and autoimmune problems.

9 Apr 2015

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

9 Apr 2015

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

St. Luke’s Cancer Center is a leader in offering clinical trials for patients with melanoma, the most unusual type of skin cancer and also the most deadly. Physicians such as Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke’s University Health Network and an internationally recognized melanoma specialist, are committed to bringing the most promising studies to the Lehigh Valley.

8 Apr 2015

Study: Key signaling pathway in B-cell lymphoma can be blocked using compounds

Cancer researchers from the University of Zurich have identified a key signaling pathway in B-cell lymphoma, a malignant type of blood cancer.

7 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC).

6 Apr 2015

Simple test outperforms current standard test for early-stage prostate cancer

A test that costs less than a $1 and yields results in minutes has been shown in newly published studies to be more sensitive and more exact than the current standard test for early-stage prostate cancer.

6 Apr 2015

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

6 Apr 2015

Novel biosensing platform could remotely determine treatment options for HIV, E-coli

In much the same way that glucometers and pregnancy tests have revolutionized in-home diagnostic testing, researchers from Florida Atlantic University and collaborators have identified a new biosensing platform that could be used to remotely detect and determine treatment options for HIV, E-coli, Staphylococcus aureas and other bacteria.

3 Apr 2015

A new amyloid-targeting treatment for Alzheimer's disease

With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.

3 Apr 2015

Antibodies News and Research

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

NIST researchers develop new 2D NMR fingerprinting method to measure monoclonal antibodies

Sterillo: The world's most hygienic hand dryer destroys bacteria and viruses

Researchers discover new biomarker to identify women with uterine cancer

Humabs BioMed reports clinical milestone in medImmune partnership

MorphoSys to receive milestone payment for guselkumab program in psoriatic arthritis

Inova Diagnostics gains FDA de novo clearance for NOVA View automated digital IFA microscope

VolitionRx adds three new laboratory automation systems to expedite sample analysis for its large ongoing clinical trials

New automated tool rapidly delivers large particles into mammalian cells

Protein-degrading enzyme can trigger strong allergic reactions through skin

Enhanced biodiversity of worms, germs associated with better immune function, overall health

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

Study: Key signaling pathway in B-cell lymphoma can be blocked using compounds

MabVax closes $11.6 million in private placement

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Simple test outperforms current standard test for early-stage prostate cancer

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Novel biosensing platform could remotely determine treatment options for HIV, E-coli

A new amyloid-targeting treatment for Alzheimer's disease

Antibodies eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News